[The effects of soluble epoxide hydrolase inhibitors on cholesterol efflux in adipocytes]

To observe the effects of soluble epoxide hydrolase inhibitors tAUCB on cholesterol efflux in adipocytes.

3T3-L1 preadipocytes were induced to differentiation and maturation. Cells were stimulated with 100 µg/L LPS after starved for 24 hours, then tAUCB in various concentrations (1, 10, 50, 100 µmol/L)were added for 24 h, or incubated with the peroxisome proliferator activated receptor gamma (PPARγ) antagonist GW9662 (5 µmol/L). 0 µmol/L tAUCB treated group was taken as empty control. After then, the mRNA expression of PPARγ and adenosine triphosphate binding cassette transporter A1(ABCA1) in cells were determined via realtime-PCR, the amounts of protein expression of PPARγ and ABCA1 in cells were detected by Western blot, the efflux rates of (3)H-cholesterol in cells were detected by means of liquid scintillation counter.

tAUCB could dose-dependently increase the apolipoprotein A1 (apoA1)-mediated cholesterol efflux in adipocytes. After stimulated by 1, 10, 50, 100 µmol/L tAUCB, cholesterol efflux rates were (5.93 ± 0.66)%, (7.40 ± 0.43)%, (8.30 ± 0.34)%, (9.77 ± 0.42)% respectively, there were significant difference after treated by 10 - 100 µmol/L tAUCB compared with control (5.67 ± 0.17)% (P < 0.05).With the concentration of tAUCB increased, ABCA1, PPARγ mRNA and protein expression were also dose-dependently up-regulated. GW9662 could significantly inhibit the effects of tAUCB, and then reduce the cholesterol efflux and the expression of PPARγ and ABCA1 in adipocytes.

tAUCB could up-regulate PPARγ expression in adipocytes, and promote the cholesterol efflux of adipocytes via apoA1-ABCA1 pathway, which might decrease the cellular cholesterol accumulation in adipocytes.